Vertex Pharmaceuticals ( VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion to $12 ...

Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for ...

What's so special about Jan. 30 for Vertex? It's the PDUFA action date set by the U.S. Food and Drug Administration (FDA) for making an approval decision on suzetrigine in treating acute pain.

The Tesla Model Y has been revamped, bringing forth new front and rear styling that echoes that of the Cybertruck. Unfortunately, the new-look Model Y is also more expensive than the former design.

[UPDATE] The recently-announced Tesla Model Y Juniper update will face pricing challenges in the U.S. reflecting a rapidly changing EV pricing landscape. The updated Model Y — already introduced ...

Q3 earnings review: Axis Bank share price tumbled over 5 per cent to hit a 52-week low during intraday trading on Friday, January 17, after the private sector lender's third-quarter (Q3FY25 ...

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...

The 2025 Tesla Model Y is here, and it’s more innovative than ever. This electric SUV showcases a bold, futuristic design paired with advanced engineering to deliver unparalleled performance.

Mumbai: Axis Bank's struggles with asset quality continued in the third quarter (October-December) of the current financial year, slowing down loan growth and hurting profitability, as the private ...

Miles keep accumulating on our long-term review 2023 Tesla Model Y, but I don’t drive it much anymore. Sure, I still go all over the place in our Tesla, but I don't drive—the car does.